天星医疗今日盘中股价大幅上涨181.22%，引起了市场的广泛关注。
消息面上，此次股价异动源于公司作为新股在港交所主板的首日挂牌交易。天星医疗的首次公开发行获得了市场的极度追捧，香港公开发售部分录得高达7,823.13倍的超额认购，国际发售部分也获得10.41倍认购，显示出投资者对其强烈的投资兴趣。市场分析认为，作为中国领先的国产运动医学植入物及器械提供商，公司在细分赛道具有龙头地位，叠加发行估值具备吸引力，共同推动了上市首日股价的强劲表现。
公开资料显示，天星医疗专注于运动医学整体解决方案，根据灼识咨询数据，按2024年销售收入计，公司为中国第四大、同时也是国产第一大运动医学植入物及器械供应商。此前在暗盘交易阶段，其股价已较发行价大幅上涨，为今日的强势开盘奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.